StockData
Odyssey Therapeutics, Inc. logo

Odyssey Therapeutics, Inc. (ODTX) stock

ODTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026
$19.37+0.01 (+0.05%)

Close on Nov 17, 2026Market cap $930.89MP/E –Yield –

Odyssey Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$36.23M–
Q1 FY2026Mar 31, 2026$32.32M–
Q2 FY2025Jun 30, 2025$30.23M–
Q1 FY2025Mar 31, 2025$38.77M–

More Odyssey Therapeutics figures

See a number that looks wrong?